How to De-Risk Complex Molecule Formulation

Posted: 06/07/16

If formulation problems surface late in the process of turning active pharmaceutical ingredients (APIs) into beneficial drugs, developers may have to change their API production processes, or even redo Phase I and Phase II trials. In "Anticipating the Formulation Challenges of Complex Molecules," an article we helped Anil Kane, Global Head of Formulation Sciences at Patheon, publish in BioProcess Online, he explains how developers can avoid that nightmare.